197 filings
6-K
AFMD
Affimed N.V.
12 Jun 24
Unaudited consolidated statements of comprehensive loss
7:56am
6-K/A
AFMD
Affimed N.V.
6 Jun 24
Current report (foreign) (amended)
5:13pm
6-K
AFMD
Affimed N.V.
3 Jun 24
Current report (foreign)
6:04am
6-K
AFMD
Affimed N.V.
28 May 24
Affimed Announces Annual General Meeting of Shareholders
6:51am
6-K
AFMD
Affimed N.V.
23 May 24
Current report (foreign)
5:22pm
6-K
4iyfzpq
28 Mar 24
Affimed Reports 2023 Financial Results and Operational Progress
4:05pm
6-K
c6r2m0 c8
11 Mar 24
Current report (foreign)
4:05pm
6-K
j0rwhr fe
6 Mar 24
Affimed Announces 1-for-10 Reverse Stock Split
6:34am
6-K
b1h3d4
8 Jan 24
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype
4:45pm
6-K
vdik9f6unp4nf2j
8 Jan 24
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
8:11am
6-K
dsrat
11 Dec 23
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1
6:10am
6-K
bu8 ijpd7zxy1j44
30 Nov 23
Current report (foreign)
7:00am
6-K
jwui0 qaiw3
14 Nov 23
Unaudited consolidated interim statements of comprehensive loss
8:31am
6-K
gys1wutvgc8lcao sw8f
4 Oct 23
Affimed Announces Listing Transfer to NASDAQ Capital Markets
6:40am
6-K
nczfcqy6v ss
10 Aug 23
Unaudited consolidated interim statements of comprehensive loss
6:45am
6-K
2lajyu3h68qrfcia9
22 Jun 23
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
6:41am
6-K
daz3rf6v v5
5 Jun 23
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohort
6:04am
6-K
oyh2dx kaxmj2sj94juh
23 May 23
Unaudited consolidated statements of comprehensive loss
6:46am
6-K
ij2he8 xnt9c56tw
22 May 23
Affimed Announces Annual General Meeting of Shareholders
6:49am